Published in Cancer Weekly, December 10th, 2002
The abstract was accepted on the first 66 evaluable patients that have completed treatment in a phase II clinical trial evaluating Onco TCS as a first-line treatment for aggressive non-Hodgkin lymphoma (NHL). All 66 patients responded to therapy for an overall response rate of 100%. Of the 66 patients, 65 (98%) completely responded to therapy and had all of their tumors eliminated and one patient (2%) partially responded to therapy and had their tumor volume decreased...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.